FI3706739T3 - Rilutsoliaihiolääkkeiden käyttö ataksioiden hoitamiseksi - Google Patents
Rilutsoliaihiolääkkeiden käyttö ataksioiden hoitamiseksi Download PDFInfo
- Publication number
- FI3706739T3 FI3706739T3 FIEP18876779.2T FI18876779T FI3706739T3 FI 3706739 T3 FI3706739 T3 FI 3706739T3 FI 18876779 T FI18876779 T FI 18876779T FI 3706739 T3 FI3706739 T3 FI 3706739T3
- Authority
- FI
- Finland
- Prior art keywords
- ataxia
- riluzole prodrug
- conh
- och
- following formula
- Prior art date
Links
- 206010003591 Ataxia Diseases 0.000 title claims 9
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 title claims 9
- 229940002612 prodrug Drugs 0.000 title claims 9
- 239000000651 prodrug Substances 0.000 title claims 9
- 229960004181 riluzole Drugs 0.000 title claims 9
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 4
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 4
- 102000007372 Ataxin-1 Human genes 0.000 claims 2
- 108010032963 Ataxin-1 Proteins 0.000 claims 2
- 102000014461 Ataxins Human genes 0.000 claims 2
- 108010078286 Ataxins Proteins 0.000 claims 2
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 2
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 201000003624 spinocerebellar ataxia type 1 Diseases 0.000 claims 2
- 108091026890 Coding region Proteins 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762584856P | 2017-11-12 | 2017-11-12 | |
| US201862717948P | 2018-08-13 | 2018-08-13 | |
| PCT/US2018/060232 WO2019094851A1 (en) | 2017-11-12 | 2018-11-11 | Use of riluzole prodrugs to treat ataxias |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3706739T3 true FI3706739T3 (fi) | 2024-12-27 |
Family
ID=66438598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP18876779.2T FI3706739T3 (fi) | 2017-11-12 | 2018-11-11 | Rilutsoliaihiolääkkeiden käyttö ataksioiden hoitamiseksi |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US20210023061A1 (enExample) |
| EP (2) | EP4483956B1 (enExample) |
| JP (2) | JP7352542B2 (enExample) |
| KR (2) | KR20250034521A (enExample) |
| CN (1) | CN112292127A (enExample) |
| AU (1) | AU2018364749C1 (enExample) |
| BR (1) | BR112020009173A2 (enExample) |
| CA (1) | CA3082096A1 (enExample) |
| DK (1) | DK3706739T3 (enExample) |
| ES (1) | ES2996892T3 (enExample) |
| FI (1) | FI3706739T3 (enExample) |
| HR (1) | HRP20241675T1 (enExample) |
| HU (1) | HUE070302T2 (enExample) |
| IL (1) | IL274532B2 (enExample) |
| LT (1) | LT3706739T (enExample) |
| MD (1) | MD3706739T2 (enExample) |
| MX (2) | MX2020004678A (enExample) |
| PH (1) | PH12020550583A1 (enExample) |
| PL (1) | PL3706739T3 (enExample) |
| PT (1) | PT3706739T (enExample) |
| RS (1) | RS66277B1 (enExample) |
| SG (1) | SG11202004332XA (enExample) |
| SI (1) | SI3706739T1 (enExample) |
| SM (1) | SMT202500022T1 (enExample) |
| WO (1) | WO2019094851A1 (enExample) |
| ZA (1) | ZA202002626B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2978158C (en) | 2015-03-03 | 2022-04-12 | Biohaven Pharmaceutical Holding Company Ltd. | Riluzole prodrugs and their use |
| US12295942B2 (en) | 2015-03-03 | 2025-05-13 | Biohaven Therapeutics Ltd. | Riluzole prodrugs and their use |
| US12029731B2 (en) | 2016-08-10 | 2024-07-09 | Biohaven Therapeutics Ltd. | Acyl benzo[d]thiazol-2-amine and their methods of use |
| EP4277624A4 (en) * | 2021-01-18 | 2024-11-20 | Biohaven Therapeutics Ltd. | USE OF RILUZOLE PRODRUGS FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| US20250101034A1 (en) * | 2021-11-04 | 2025-03-27 | Skyhawk Therapeutics, Inc. | Compositions useful for modulating splicing |
| CN120018855A (zh) * | 2022-05-23 | 2025-05-16 | 拜奥海芬治疗学有限公司 | 治疗脊髓小脑性共济失调的方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1548022A (en) | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
| WO1995001782A2 (en) | 1993-07-09 | 1995-01-19 | R.P. Scherer Corporation | Method for making freeze dried drug dosage forms |
| US5457895A (en) | 1993-10-01 | 1995-10-17 | R. P. Scherer Corporation | Method of identifying freeze-dried dosage forms |
| US5837287A (en) | 1994-10-28 | 1998-11-17 | R P Scherer Corporation | Process for preparing solid pharmaceutical dosage forms |
| WO1998036738A1 (en) | 1997-02-20 | 1998-08-27 | Therics, Inc. | Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same |
| EP1001748B1 (en) | 1997-07-25 | 2006-04-19 | Alpex Pharma S.A. | A process for the preparation of a granulate suitable to the preparation of rapidly disintegrable mouth-soluble tablets |
| FR2774592B1 (fr) * | 1998-02-06 | 2000-03-17 | Rhone Poulenc Rorer Sa | Application du 2-amino-6-trifluoromethoxybenzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet |
| RU2233654C2 (ru) | 1998-11-20 | 2004-08-10 | Ртп Фарма Инк. | Диспергируемые стабилизированные фосфолипидом микрочастицы |
| GB9908014D0 (en) | 1999-04-08 | 1999-06-02 | Scherer Corp R P | Pharmaceutical compositions |
| US6284270B1 (en) | 1999-08-04 | 2001-09-04 | Drugtech Corporation | Means for creating a mass having structural integrity |
| US6316029B1 (en) | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| US6814978B2 (en) | 2000-12-29 | 2004-11-09 | Mcneil-Ppc, Inc. | Process for preparing a soft tablet |
| US6509040B1 (en) | 2001-06-22 | 2003-01-21 | R.P. Scherer Corporation | Fast dispersing dosage forms essentially free of mammalian gelatin |
| AU2002334939A1 (en) | 2001-10-12 | 2003-04-22 | Eugene R. Cooper | Compositions having a combination of particles for immediate release and for controlled release |
| EP1485296B1 (en) | 2002-02-13 | 2011-07-20 | Michael K. Weibel | Drug dose - form and method of manufacture |
| ATE337003T1 (de) * | 2003-04-28 | 2006-09-15 | Biofrontera Bioscience Gmbh | Verwendung von riluzole kombiniert mit geeigneten hilfs-und zusatzstoffen zur behandlung von krankheiten, die durch eine hyperproliferation von keratinozyten gekennzeichnet sind, insbesondere neurodermitis und psoriasis |
| US7282217B1 (en) | 2003-08-29 | 2007-10-16 | Kv Pharmaceutical Company | Rapidly disintegrable tablets |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| US8048449B2 (en) | 2005-12-27 | 2011-11-01 | Jubilant Organosys Ltd. | Mouth dissolving pharmaceutical composition and process for preparing the same |
| WO2009002084A2 (en) | 2007-06-27 | 2008-12-31 | Hanmi Pharm. Co., Ltd. | Method for preparing rapidly disintegrating formulation for oral administration and apparatus for preparing and packing the same |
| JP2011516489A (ja) * | 2008-03-31 | 2011-05-26 | ユニバーシティ・オブ・サウス・フロリダ | 疾患誘発性運動失調症および非運動失調性平衡異常の治療法 |
| US8221480B2 (en) | 2008-10-31 | 2012-07-17 | The Invention Science Fund I, Llc | Compositions and methods for biological remodeling with frozen particle compositions |
| US8256233B2 (en) | 2008-10-31 | 2012-09-04 | The Invention Science Fund I, Llc | Systems, devices, and methods for making or administering frozen particles |
| US8313768B2 (en) | 2009-09-24 | 2012-11-20 | Mcneil-Ppc, Inc. | Manufacture of tablet having immediate release region and sustained release region |
| CA2978158C (en) * | 2015-03-03 | 2022-04-12 | Biohaven Pharmaceutical Holding Company Ltd. | Riluzole prodrugs and their use |
-
2018
- 2018-11-11 JP JP2020526149A patent/JP7352542B2/ja active Active
- 2018-11-11 HU HUE18876779A patent/HUE070302T2/hu unknown
- 2018-11-11 CN CN201880073828.6A patent/CN112292127A/zh active Pending
- 2018-11-11 KR KR1020257006278A patent/KR20250034521A/ko active Pending
- 2018-11-11 CA CA3082096A patent/CA3082096A1/en active Pending
- 2018-11-11 BR BR112020009173-1A patent/BR112020009173A2/pt unknown
- 2018-11-11 ES ES18876779T patent/ES2996892T3/es active Active
- 2018-11-11 PL PL18876779.2T patent/PL3706739T3/pl unknown
- 2018-11-11 SM SM20250022T patent/SMT202500022T1/it unknown
- 2018-11-11 DK DK18876779.2T patent/DK3706739T3/da active
- 2018-11-11 US US16/762,165 patent/US20210023061A1/en active Pending
- 2018-11-11 AU AU2018364749A patent/AU2018364749C1/en active Active
- 2018-11-11 RS RS20241371A patent/RS66277B1/sr unknown
- 2018-11-11 SI SI201831180T patent/SI3706739T1/sl unknown
- 2018-11-11 IL IL274532A patent/IL274532B2/en unknown
- 2018-11-11 HR HRP20241675TT patent/HRP20241675T1/hr unknown
- 2018-11-11 SG SG11202004332XA patent/SG11202004332XA/en unknown
- 2018-11-11 LT LTEPPCT/US2018/060232T patent/LT3706739T/lt unknown
- 2018-11-11 EP EP24199849.1A patent/EP4483956B1/en active Active
- 2018-11-11 PT PT188767792T patent/PT3706739T/pt unknown
- 2018-11-11 KR KR1020207016775A patent/KR20200103658A/ko not_active Ceased
- 2018-11-11 EP EP18876779.2A patent/EP3706739B1/en active Active
- 2018-11-11 FI FIEP18876779.2T patent/FI3706739T3/fi active
- 2018-11-11 MX MX2020004678A patent/MX2020004678A/es unknown
- 2018-11-11 MD MDE20200953T patent/MD3706739T2/ro unknown
- 2018-11-11 WO PCT/US2018/060232 patent/WO2019094851A1/en not_active Ceased
-
2020
- 2020-05-08 PH PH12020550583A patent/PH12020550583A1/en unknown
- 2020-05-11 ZA ZA2020/02626A patent/ZA202002626B/en unknown
- 2020-07-13 MX MX2023012640A patent/MX2023012640A/es unknown
-
2023
- 2023-07-17 US US18/353,840 patent/US12102618B2/en active Active
- 2023-07-17 US US18/353,850 patent/US20230355592A1/en active Pending
- 2023-09-15 JP JP2023149803A patent/JP2023175823A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3706739T3 (fi) | Rilutsoliaihiolääkkeiden käyttö ataksioiden hoitamiseksi | |
| CO2021009078A2 (es) | Pirazolopirimidinas sustituidas y purinas sustituidas y su uso como inhibidores de proteasa procesadora específica de ubiquitina 1 (usp1) | |
| MX390793B (es) | Amidas de piridona deuteradas y sus profármacos como moduladores de los canales de sodio. | |
| ZA202202361B (en) | Treatment of hidradenitis suppurativa using jak inhibitors | |
| CY1126039T1 (el) | Ενωσεις και συνθεσεις ουριας ως αναστολεις της ατρ-ασης smarca2/brm | |
| WO2012158413A3 (en) | Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors | |
| DE602007014186D1 (de) | Triazin-11-beta-hydroxysteroid-dehydrogenase-artige hemmer | |
| MX2020006599A (es) | Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central. | |
| PH12015500719A1 (en) | Gdf-8-inhibitors | |
| NZ590727A (en) | Benzoxazines, benzothiazines, and related compounds having nos inhibitory activity | |
| WO2023129958A3 (en) | Nitric oxide releasing prodrugs of mda and mdma | |
| TN2014000210A1 (en) | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives | |
| CY1110770T1 (el) | Χρηση των (r)-(αλογονοβενζυλοξυ) βενζυλαμινο-προπαναμιδιων ως επιλεκτικων διαμορφωτων διαυλου νατριου και/ή ασβεστιου | |
| WO2018102687A3 (en) | Combination therapy for treating cancer | |
| MX2011008910A (es) | Derivados de azol sustituidos, composicion farmaceutica que comprende los derivados, y uso de los derivados para tratar enfermeda de parkinson. | |
| ZA202006072B (en) | Ret inhibitor for use in treating cancer having a ret alteration | |
| BR112023019309A2 (pt) | Tratamento de hidradenite supurativa com orismilaste | |
| PH12020551772A1 (en) | Oxo-substituted compound | |
| CL2011001829A1 (es) | 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo. | |
| PH12020500542A1 (en) | Dopamine-b-hydroxylase inhibitors | |
| MX2023010506A (es) | Composiciones que comprenden profarmacos de escision enzimatica y nafamostat de liberacion controlada y metodos de uso de estos. | |
| MX2023003332A (es) | Inhibidores del elemento 1 interdispersado largo (line-1) para el tratamiento de enfermedades. | |
| BR112021017198A2 (pt) | Uso de vibegron para tratar bexiga hiperativa | |
| MX2021015390A (es) | Tratamiento para sinucleinopatias. | |
| BR112016017313A2 (pt) | Composto, composição farmacêutica, inibidor da atividade da atpase de um complexo tip48/tip49, e, agentes antitumor e terapêutico para um tumor |